The antiviral activity of azidothymidine (AZT), dideoxycytidine (ddC), and dideoxyinosine (ddI) against HIV-1 was comparatively evaluated in PHA-stimulated PBM. The mean drug concentration which yielded 50% p24 Gag negative cultures were substantially different: 0.06, 0.2, and 6 microM for AZT, ddC, and ddI, respectively. We found that AZT was preferentially phosphorylated to its triphosphate (TP) form in PHA-PBM rather than unstimulated, resting PBM (R-PBM), producing 10- to 17-fold higher ratios of AZTTP/dTTP in PHA-PBM than in R-PBM. The phosphorylation of ddC and ddI to their TP forms was, however, much less efficient in PHA-PBM, resulting in approximately 5-fold and approximately 15-fold lower ratios of ddCTP/dCTP and ddATP/dATP, respectively, in PHA-PBM than in R-PBM. The comparative order of PHA-induced increase in cellular enzyme activities examined was: thymidine kinase > uridine kinase > deoxycytidine kinase > adenosine kinase > 5'-nucleotidase. We conclude that AZT, ddC, and ddI exert disproportionate antiviral effects depending on the activation state of the target cells, i.e., ddI and ddC exert antiviral activity more favorably in resting cells than in activated cells, while AZT preferentially protects activated cells against HIV infection. Considering that HIV-1 proviral DNA synthesis in resting lymphocytes is reportedly initiated at levels comparable with those of activated lymphocytes, the current data should have practical relevance in the design of anti-HIV chemotherapy, particularly combination chemotherapy.
W Y Gao, T Shirasaka, D G Johns, S Broder, H Mitsuya
Title and authors | Publication | Year |
---|---|---|
The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter
Apetroaei MM, Velescu BȘ, Nedea MI, Dinu-Pîrvu CE, Drăgănescu D, Fâcă AI, Udeanu DI, Arsene AL |
Biomedicines | 2024 |
Identification of SARS-CoV-2 M(pro) inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2.
Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, Takamune N, Kishimoto N, Hattori SI, Das D, Uemura Y, Shimizu Y, Aoki M, Hasegawa K, Suzuki S, Nishiyama A, Saruwatari J, Shimizu Y, Sukenaga Y, Takamatsu Y, Tsuchiya K, Maeda K, Yoshimura K, Iida S, Ozono S, Suzuki T, Okamura T, Misumi S, Kawaoka Y, Tamamura H, Mitsuya H |
Nature Communications | 2023 |
Genital immune cell activation and tenofovir gel efficacy in women at risk of HIV infection
Lenine Liebenberg, Jo-Ann Passmore, Farzana Osman, Janine Jewanraj, Andile Mtshali, J. Garcia-Lerma, Walid Heneine, Angela Holder, Derseree Archary, Sinaye Ngcapu, Aida Sivro, Leila Mansoor, Quarraisha Karim, Salim Karim, Lyle McKinnon |
Clinical Infectious Diseases | 2022 |
Non-structural protein 5 (NS5) as a target for antiviral development against established and emergent flaviviruses
PO Fernandes, MA Chagas, WR Rocha, AH Moraes |
Current Opinion in Virology | 2021 |
Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine
JB Dumond, CP Bay, JA Nelson, A Davalos, A Edmonds, KD Paris, C Sykes, K Anastos, R Sharma, S Kassaye, B Tamraz, AL French, S Gange, I Ofotokun, MA Fischl, DE Vance, AA Adimora |
Antimicrobial agents and chemotherapy | 2020 |
Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses
L Eyer, R Nencka, E de Clercq, K Seley-Radtke, D Růžek |
Antiviral Chemistry and Chemotherapy | 2018 |
Arbidol (Umifenovir): A Broad-Spectrum Antiviral Drug That Inhibits Medically Important Arthropod-Borne Flaviviruses
J Haviernik, M Štefánik, M Fojtíková, S Kali, N Tordo, I Rudolf, Z Hubálek, L Eyer, D Ruzek |
Viruses | 2018 |
Chalcogenozidovudine Derivatives With Antitumor Activity: Comparative Toxicities in Cultured Human Mononuclear Cells
A Ecker, PC Ledur, RS da Silva, DB Leal, OE Rodrigues, D Ardisson-Araújo, EP Waczuk, JB da Rocha, NV Barbosa |
Toxicological Sciences | 2017 |
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
V Boldescu, MA Behnam, N Vasilakis, CD Klein |
Nature Reviews Drug Discovery | 2017 |
Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics.
Holec AD, Mandal S, Prathipati PK, Destache CJ |
Current HIV research | 2017 |
The Medicinal Chemistry of Dengue Virus
MA Behnam, C Nitsche, V Boldescu, CD Klein |
Journal of Medicinal Chemistry | 2016 |
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
ML Cottrell, KH Yang, HM Prince, C Sykes, N White, S Malone, ES Dellon, RD Madanick, NJ Shaheen, MG Hudgens, J Wulff, KB Patterson, JA Nelson, AD Kashuba |
The Journal of Infectious Diseases | 2016 |
Exposure to zidovudine adversely affects mitochondrial turnover in primary T cells
ZR Wallace, S Sanderson, AK Simon, L Dorrell |
Antiviral Research | 2016 |
Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread
K Shimura, P Miyazato, S Oishi, N Fujii, M Matsuoka |
Virology | 2015 |
The search for nucleoside/nucleotide analog inhibitors of dengue virus
YL Chen, F Yokokawa, PY Shi |
Antiviral Research | 2015 |
SAMHD1 Specifically Affects the Antiviral Potency of Thymidine Analog HIV Reverse Transcriptase Inhibitors
E Ballana, R Badia, G Terradas, J Torres-Torronteras, A Ruiz, E Pauls, E Riveira-Munoz, B Clotet, R Marti, JA Este |
Antimicrobial agents and chemotherapy | 2014 |
Depot-Medroxyprogesterone Acetate Does Not Reduce the Prophylactic Efficacy of Emtricitabine and Tenofovir Disoproxil Fumarate in Macaques:
J Radzio, K Hanley, J Mitchell, S Ellis, F Deyounks, L Jenkins, W Heneine, JG García-Lerma |
Journal of acquired immune deficiency syndromes (1999) | 2014 |
Pharmacology Lessons From Chemoprophylaxis Studies
M Boffito, A Jackson, D Asboe |
Clinical Infectious Diseases | 2014 |
Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention
A Jackson, G Moyle, V Watson, J Tjia, A Ammara, D Back, M Mohabeer, B Gazzard, M Boffito |
Journal of acquired immune deficiency syndromes (1999) | 2013 |
Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir
YL Chen, NA Ghafar, R Karuna, Y Fu, SP Lim, W Schul, F Gu, M Herve, F Yokohama, G Wang, D Cerny, K Fink, F Blasco, PY Shi |
Journal of virology | 2013 |
Ten years of dengue drug discovery: Progress and prospects
SP Lim, QY Wang, CG Noble, YL Chen, H Dong, B Zou, F Yokokawa, S Nilar, P Smith, D Beer, J Lescar, PY Shi |
Antiviral Research | 2013 |
Human Immunodeficiency Virus Reverse Transcriptase
S LeGrice, M Gotte |
2013 | |
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine
JE Rower, A Meditz, EM Gardner, K Lichtenstein, J Predhomme, LR Bushman, B Klein, JH Zheng, S Mawhinney, PL Anderson |
Antimicrobial agents and chemotherapy | 2012 |
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects
A Jackson, G Moyle, L Dickinson, D Back, S Khoo, J Taylor, K Gedela, G Abongomera, B Gazzard, M Boffito |
Antiviral therapy | 2012 |
Anti-HIV nucleoside drugs: A retrospective view into the future
MK Kukhanova |
Molecular Biology | 2012 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Advances in Mitochondrial Medicine
R Scatena, P Bottoni, B Giardina |
Advances in Mitochondrial Medicine | 2011 |
Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions
L Enomoto, PL Anderson, S Li, CL Edelstein, A Weinberg |
AIDS Research and Human Retroviruses | 2011 |
The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection
E Pretorius, H Klinker, B Rosenkranz |
Therapeutic Drug Monitoring | 2011 |
Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors
JG Garcia-Lerma, W Aung, M Cong, Q Zheng, AS Youngpairoj, J Mitchell, A Holder, A Martin, S Kuklenyik, W Luo, CY Lin, DL Hanson, E Kersh, CP Pau, AS Ray, JF Rooney, WA Lee, W Heneine |
Journal of virology | 2011 |
Pre-steady-state kinetic analysis of the incorporation of anti-HIV nucleotide analogs catalyzed by human X- and Y-family DNA polymerases
JA Brown, LR Pack, JD Fowler, Z Suo |
Antimicrobial agents and chemotherapy | 2010 |
Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine
T Cihlar, AS Ray |
Antiviral Research | 2010 |
Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action
S Khalili, JM Monaco, A Armaou |
Journal of Theoretical Biology | 2010 |
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
VG Fowler, WM Scheld, AS Bayer |
Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases | 2010 |
Decomposition of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate (AZTMP) prodrugs in biological media studied by on-line solid-phase extraction coupled to liquid chromatography mass spectrometry
I Lefebvre, T Beltran, S Peyrottes, C Périgaud |
Biomedical Chromatography | 2009 |
Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors
TC Jessop, JE Tarver, M Carlsen, A Xu, JP Healy, A Heim-Riether, Q Fu, JA Taylor, DJ Augeri, M Shen, TR Stouch, RV Swanson, LW Tari, M Hunter, I Hoffman, PE Keyes, XC Yu, M Miranda, Q Liu, JC Swaffield, SD Kimball, A Nouraldeen, AG Wilson, AM Foushee, K Jhaver, R Finch, S Anderson, T Oravecz, KG Carson |
Bioorganic & Medicinal Chemistry Letters | 2009 |
Effector caspase activation, in the absence of a conspicuous apoptosis induction, in mononuclear cells treated with azidothymidine
C Matteucci, A Minutolo, E Balestrieri, A Ascolani, S Grelli, B Macchi, A Mastino |
Pharmacological research : the official journal of the Italian Pharmacological Society | 2009 |
Anti-Human Immunodeficiency Virus Activity, Cross-Resistance, Cytotoxicity, and Intracellular Pharmacology of the 3′-Azido-2′,3′-Dideoxypurine Nucleosides
N Sluis-Cremer, D Koontz, L Bassit, BI Hernandez-Santiago, M Detorio, KL Rapp, F Amblard, L Bondada, J Grier, SJ Coats, RF Schinazi, JW Mellors |
Antimicrobial agents and chemotherapy | 2009 |
DNA polymerases as therapeutic targets
AJ Berdis |
Biochemistry | 2008 |
Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro
PL Anderson, T King, JH Zheng, S MaWhinney |
The Journal of antimicrobial chemotherapy | 2008 |
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men
JB Dumond, YS Reddy, L Troiani, JF Rodriguez, AS Bridges, SA Fiscus, GJ Yuen, MS Cohen, AD Kashuba |
Journal of acquired immune deficiency syndromes (1999) | 2008 |
Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs
PL Anderson |
Current Opinion in HIV and AIDS | 2008 |
Simultaneous determination of endogenous deoxynucleotides and phosphorylated nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cells using ion-pair liquid chromatography coupled to mass spectrometry
L Coulier, JJ van Kampen, R Groot, HW Gerritsen, RC Bas, WD van Dongen, LP Brüll, TM Luider |
PROTEOMICS - CLINICAL APPLICATIONS | 2008 |
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults
PL Anderson, JH Zheng, T King, LR Bushman, J Predhomme, A Meditz, J Gerber, CV Fletcher |
AIDS | 2007 |
HIV-1 reverse transcriptase inhibitors
Y Safadi, V Vivet-Boudou, R Marquet |
Applied Microbiology and Biotechnology | 2007 |
Comparative evaluation of the activity of antivirals towards feline immunodeficiency virus in different cell culture systems
FJ der Meer, NM Schuurman, J Balzarini, HF Egberink |
Antiviral Research | 2007 |
Prodrugs
VJ Stella, RT Borchardt, MJ Hageman, R Oliyai, H Maag, JW Tilley |
2007 | |
Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages
D Perez-Bercoff, S Wurtzer, S Compain, H Benech, F Clavel |
Journal of virology | 2007 |
Activity against Human Immunodeficiency Virus Type 1, Intracellular Metabolism, and Effects on Human DNA Polymerases of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine
H Nakata, M Amano, Y Koh, E Kodama, G Yang, CM Bailey, S Kohgo, H Hayakawa, M Matsuoka, KS Anderson, YC Cheng, H Mitsuya |
Antimicrobial agents and chemotherapy | 2007 |
Evidence and Possible Consequences of the Phosphorylation of Nucleoside Reverse Transcriptase Inhibitors in Human Red Blood Cells
L Durand-Gasselin, DD Silva, H Benech, A Pruvost, J Grassi |
Antimicrobial agents and chemotherapy | 2007 |
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children:
C Giaquinto, O Rampon, M Penazzato, F Fregonese, AD Rossi, R DElia |
Clinical Drug Investigation | 2007 |
R5 Variants of Human Immunodeficiency Virus Type 1 Preferentially Infect CD62L − CD4 + T Cells and Are Potentially Resistant to Nucleoside Reverse Transcriptase Inhibitors
F Gondois-Rey, A Biancotto, MA Fernandez, L Bettendroffer, J Blazkova, K Trejbalova, M Pion, I Hirsch |
Journal of virology | 2006 |
Reverse Transcriptase Inhibitors in HIV/AIDS Therapy
V St.Georgiev, G Skowron, R Ogden, JM Lange |
2006 | |
Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients
O Turriziani, O Butera, N Gianotti, SG Parisi, R Mazzi, E Girardi, G Iaiani, L Antonelli, A Lazzarin, G Antonelli |
AIDS | 2005 |
Antiviral Therapies in Children: Has Their Time Arrived?
DW Kimberlin |
Pediatric Clinics of North America | 2005 |
Therapeutic Drug Monitoring: Role for a Pharmacist in Multidisciplinary Antiretroviral Management
JC Slish, LM Catanzaro, O Okusanya, LM Demeter, M Albrecht, R Difrancesco, GD Morse |
Journal of Pharmacy Practice | 2005 |
Pharmacokinetics of Antiretroviral Therapy in HIV-1-Infected Children:
PL Fraaij, JJ van Kampen, DM Burger, R de Groot |
Clinical Pharmacokinetics | 2005 |
Effect of Cell Cycle Arrest on the Activity of Nucleoside Analogues against Human Immunodeficiency Virus Type 1
S Wurtzer, S Compain, H Benech, AJ Hance, F Clavel |
Journal of virology | 2005 |
Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation
CP Locher, SA Witt, R Kassel, NL Dowell, S Fujimura, JA Levy |
Journal of General Virology | 2005 |
Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro
J Saavedra-Lozano, CC McCoig, Y Cao, ES Vitetta, O Ramilo |
Antimicrobial agents and chemotherapy | 2004 |
A new method for analysis of AZT-triphosphate and nucleotide-triphosphates
JJ van Kampen, PL Fraaij, V Hira, AM van Rossum, NG Hartwig, R Groot, TM Luider |
Biochemical and Biophysical Research Communications | 2004 |
Therapeutic Drug Monitoring in Children with HIV/AIDS
PL Fraaij, N Rakhmanina, DM Burger, R Groot |
Therapeutic Drug Monitoring | 2004 |
Activity, Safety, and Immunological Effects of Hydroxyurea Added to Didanosine in Antiretroviral-Naive and Experienced HIV Type 1-Infected Subjects: A Randomized, Placebo-Controlled Trial, ACTG 307
I Frank, RJ Bosch, S Fiscus, F Valentine, C Flexner, Y Segal, P Ruan, R Gulick, K Wood, S Estep, L Fox, T Nevin, M Stevens, JJ Eron |
AIDS Research and Human Retroviruses | 2004 |
The Cellular Pharmacology of Nucleoside‐ and Nucleotide‐Analogue Reverse‐Transcriptase Inhibitors and Its Relationship to Clinical Toxicities
PL Anderson, TN Kakuda, KA Lichtenstein |
Clinical Infectious Diseases | 2004 |
Pharmacokinetic Properties of Nucleoside/Nucleotide Reverse Transcriptase Inhibitors:
PJ Piliero |
Journal of acquired immune deficiency syndromes (1999) | 2004 |
Combination Therapy of AIDS
ED Clercq, AM Vandamme |
2004 | |
Real Versus Virtual Phenotype to Guide Treatment in Heavily Pretreated Patients: 48-Week Follow-Up of the Genotipo-Fenotipo di Resistenza (GenPheRex) Trial
F Mazzotta, SL Caputo, C Torti, C Tinelli, P Pierotti, F Castelli, A Lazzarin, G Angarano, R Maserati, N Gianotti, N Ladisa, E Quiros-Roldan, AR Rinehart, G Carosi |
JAIDS Journal of Acquired Immune Deficiency Syndromes | 2003 |
Investigation of nucleoside analogs with anti-HIV activity
M Arissawa, CA Taft, J Felcman |
International Journal of Quantum Chemistry | 2003 |
Replication Kinetics for Divergent Type 1 Human Immunodeficiency Viruses Using Quantitative SYBR Green I Real-Time Polymerase Chain Reaction
JG Victoria, DJ Lee, BR McDougall, WE Robinson |
AIDS Research and Human Retroviruses | 2003 |
Pharmacodynamics and clinical use of anti-HIV drugs
SL Preston, PJ Piliero, GL Drusano |
Infectious Disease Clinics of North America | 2003 |
PHARMACOLOGICAL AND BIOLOGICAL ASPECTS OF BASIC RESEARCH ON NUCLEOSIDE-BASED REVERSE TRANSCRIPTASE INHIBITORS
B Macchi, A Mastino |
Pharmacological Research | 2002 |
Immunomodulatory effect of zidovudine (ZDV) on cytotoxic T lymphocytes previously exposed to ZDV
S Francke, CG Orosz, J Hsu, LE Mathes |
Antimicrobial agents and chemotherapy | 2002 |
Genotypic testing for human immunodeficiency virus type 1 drug resistance
RW Shafer |
Clinical microbiology reviews | 2002 |
HIV-1 drug resistance: can we overcome?
BG Brenner, MA Wainberg, D Turner |
Expert Opinion on Biological Therapy | 2002 |
Activity of Reverse Transcriptase Inhibitors in Monocyte-Derived Dendritic Cells: A Possiblein VitroModel for Postexposure Prophylaxis of Sexual HIV Transmission
YV Herrewege, L Penne, C Vereecken, K Fransen, G der Groen, L Kestens, J Balzarini, G Vanham |
AIDS Research and Human Retroviruses | 2002 |
Antiretroviral pharmacokinetics in the paediatric population: a review.
King JR, Kimberlin DW, Aldrovandi GM, Acosta EP |
Clinical Pharmacokinetics | 2002 |
Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo
PG Hoggard, SD Sales, D Phiboonbanakit, J Lloyd, BA Maher, SH Khoo, E Wilkins, P Carey, CA Hart, DJ Back |
Antimicrobial agents and chemotherapy | 2001 |
Mitochondrial toxicity associated with nucleoside reverse transcriptase inhibitor therapy
CM Shikuma, B Shiramizu |
Current Infectious Disease Reports | 2001 |
Testing the reverse transcriptase model of somatic mutation
SZ Sack, PD Bardwell, MD Scharff |
Molecular Immunology | 2001 |
Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians
DS Stein, KH Moore |
Pharmacotherapy | 2001 |
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies
RW Shafer, K Dupnik, MA Winters, SH Eshleman |
HIV sequence compendium | 2001 |
Zidovudine Phosphorylation and Mitochondrial Toxicity in Vitro
SD Sales, PG Hoggard, D Sunderland, S Khoo, CA Hart, DJ Back |
Toxicology and Applied Pharmacology | 2001 |
Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy:
FD Goebel, R Hemmer, JC Schmit, JR Bogner, E Clercq, M Witvrouw, C Pannecouque, R Valeyev, M Vandevelde, H Margery, JP Tassignon |
AIDS | 2001 |
Plasma Drug Levels Compared with DNA Incorporation of 3′-azido-3′-Deoxythymidine (AZT) in Adult Cynomolgus (Macaca fascicularis) Monkeys
OA Olivero, MK Reddy, SM Pietras, MC Poirier |
Experimental biology and medicine (Maywood, N.J.) | 2001 |
Thymidine Kinase-Independent Intracellular Delivery of Bioactive Nucleotides by Aryl Phosphate Derivatives of Bromo-Methoxy Zidovudine (Compounds WHI-05 and WHI-07) in Normal Human Female Genital Tract Epithelial Cells and Sperm1
OJ DCruz, TK Venkatachalam, FM Uckun |
Biology of reproduction | 2001 |
Atlas of AIDS
GL Mandell, D Mildvan |
2001 | |
Mitochondrial Toxicity Associated with Nucleoside Reverse Transcriptase Inhibitor Therapy.
Shikuma CM, Shiramizu B |
Current Infectious Disease Reports | 2001 |
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors
RW Shafer, R Kantor, MJ Gonzales |
AIDS reviews | 2000 |
Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection
S Piconi, D Trabattoni, ML Fusi, F Milazzo, LP Dix, G Rizzardini, F Colombo, D Bray, M Clerici |
Antiviral Research | 2000 |
Antileukemic activity and mechanism of action of cordycepin against terminal deoxynucleotidyl transferase-positive (TdT+) leukemic cells
E Kodama |
Biochemical Pharmacology | 2000 |
Simultaneous quantitation of the 5′-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry
JD Moore, G Valette, A Darque, XJ Zhou, JP Sommadossi |
Journal of the American Society for Mass Spectrometry | 2000 |
Antiviral Resistance of Biologic HIV-2 Clones Obtained From Individuals on Nucleoside Reverse Transcriptase Inhibitor Therapy
ME van der Ende, C Guillon, PH Boers, TD Ly, RA Gruters, AD Osterhaus, M Schutten |
JAIDS Journal of Acquired Immune Deficiency Syndromes | 2000 |
Phase II Placebo-Controlled Trial of Fozivudine Tidoxil for HIV Infection: Pharmacokinetics, Tolerability, and Efficacy
PM Girard, PS Pegram, B Diquet, R Anderson, F Raffi, R Tubiana, D Sereni, D Boerner |
JAIDS Journal of Acquired Immune Deficiency Syndromes | 2000 |
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
TN Kakuda |
Clinical Therapeutics | 2000 |
Potentiation of The Anti-HIV Activity of Zalcitabine and Lamivudine by a CTP Synthase Inhibitor, 3-Deazauridine
WY Gao, DG Johns, H Mitsuya |
Nucleosides Nucleotides & Nucleic Acids | 2000 |
Simultaneous determination of zidovudine and its monophosphate in mouse plasma and peripheral red blood cells by high-performance liquid chromatography
X Tan, FD Boudinot |
Journal of Chromatography B: Biomedical Sciences and Applications | 2000 |
AIDS-Related Cancers and Their Treatment
S Miles |
AIDS-Related Cancers and Their Treatment | 2000 |
Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons:
CV Fletcher, SP Kawle, TN Kakuda, PL Anderson, D Weller, LR Bushman, RC Brundage, RP Remmel |
AIDS | 2000 |
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients:
K Ruxrungtham, ED Kroon, C Ungsedhapand, S Teeratakulpisarn, S Ubolyam, S Buranapraditkun, R Leeuwen, GJ Weverling, C Kunanusont, JM Lange, DA Cooper, P Phanuphak |
AIDS | 2000 |
Pharmacokinetics of Bis(t-butyl-SATE)-AZTMP, a Bispivaloylthioethyl Prodrug for Intracellular Delivery of Zidovudine Monophosphate, in Mice
X Tan, FD Boudinot, CK Chu, D Egron, C Perigaud, G Gosselin, JL Imbach |
Antiviral Chemistry & Chemotherapy | 2000 |
Diminished Human Immunodeficiency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G 1 Phase of the Cell Cycle
NA Kootstra, BM Zwart, H Schuitemaker |
Journal of virology | 2000 |
Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
Moore JD, Valette G, Darque A, Zhou XJ, Sommadossi JP |
Journal of the American Society for Mass Spectrometry | 2000 |
Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients
A Darque, G Valette, F Rousseau, LH Wang, JP Sommadossi, XJ Zhou |
Antimicrobial agents and chemotherapy | 1999 |
Reverse transcriptase inhibitors can selectively block the synthesis of differently sized viral DNA transcripts in cells acutely infected with human immunodeficiency virus type 1
Y Quan, L Rong, C Liang, MA Wainberg |
Journal of virology | 1999 |
Use of a non-adherent cell culture system for testing the effect of 2â²,3â²-dideoxyinosine againstCryptosporidium parvum
P Lawton, C Hejl, ME Sarciron, R Mancassola, M Naciri, AF Petavy |
FEMS Microbiology Letters | 1999 |
Highly active antiretroviral therapy (Haart) for the treatment of infection with human immunodeficiency virus type 1
R Shafer, D Vuitton |
Biomedecine & Pharmacotherapy | 1999 |
Safety and Antiretroviral Effects of Combined Didanosine and Stavudine Therapy in HIV-Infected Individuals With CD4 Counts of 200 to 500 cells/mm3
RB Pollard, D Peterson, D Hardy, J Pottage, RL Murphy, J Gathe, G Beall, V Rutkievicz, L Reynolds, AP Cross, LM Dunkle |
Journal of Acquired Immune Deficiency Syndromes | 1999 |
Transport, metabolism and elimination mechanisms of anti-HIV agents
X Li, WK Chan |
Advanced Drug Delivery Reviews | 1999 |
Intracellular Activation of 2',3'-Dideoxyinosine and Drug Interactions in Vitro
S Kewn, PG Hoggard, JS Henry-Mowatt, GJ Veal, SD Sales, MG Barry, DJ Back |
AIDS Research and Human Retroviruses | 1999 |
Intracellular Phosphorylation of Zidovudine in an In Vitro Hollow Fiber Model
KZ Rana, MN Dudley |
Pharmacotherapy | 1999 |
Synthesis of a non-hydrolyzable AZT-triphosphate analogue designed for the production of anti-AZT-TP antibodies
T Brossette, A Valleix, L Goujon, C Cre´minon, J Grassi, C Mioskowski, L Lebeau |
Tetrahedron Letters | 1999 |
HIV and the New Viruses
S McAdam, F Gotch |
HIV and the New Viruses | 1999 |
Advances in Antiviral Drug Design
MN Arimilli, JP Dougherty, KC Cundy, N Bischofberger |
Advances in Antiviral Drug Design | 1999 |
Early Steps of Replication of Moloney Murine Leukemia Virus in Resting Lymphocytes
L Piéroni, P Bouillé, C Auclair, JJ Guillosson, J Nafziger |
Virology | 1999 |
Nonproductive Human Immunodeficiency Virus Type 1 Infection in Nucleoside-Treated G 0 Lymphocytes
YD Korin, JA Zack |
Journal of virology | 1999 |
Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors
GJ Veal, S Agrawal, RA Byrn |
Antiviral Research | 1998 |
Effect of Ribavirin on Zidovudine Efficacy and Toxicityin Vitro: A Concentration-Dependent Interaction
S Sim, P Hoggard, S Sales, D Phiboonbanakit, C Hart, D Back |
AIDS Research and Human Retroviruses | 1998 |
Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo
AB van Wout, LJ Ran, M Nijhuis, JM Tijnagel, T Groot, R Leeuwen, CA Boucher, H Schuitemaker, R Schuurman |
AIDS | 1998 |
Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity
EJ Arts, ME Quiñones-Mateu, JL Albright |
Drug Resistance Updates | 1998 |
High-Performance Liquid Chromatographic Method for the Determination of Intracellular dTTP Pools
D Siccardi, AD Ranieri, A Jayewardene, JG Gambertoglio |
Journal of Liquid Chromatography & Related Technologies | 1998 |
Monitoring of intracellular levels of 5′-monophosphate-AZT using an enzyme immunoassay
L Goujon, T Brossette, N Dereudre-Bosquet, C Creminon, P Clayette, D Dormont, C Mioskowski, L Lebeau, J Grassi |
Journal of Immunological Methods | 1998 |
Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine
W Y Gao, B S Zhou, D G Johns, H Mitsuya, Y Yen |
Biochemical Pharmacology | 1998 |
Intracellular Nucleotides of (−)-2′,3′-Deoxy-3′-Thiacytidine in Peripheral Blood Mononuclear Cells of a Patient Infected with Human Immunodeficiency Virus
C Solas, YF Li, MY Xie, JP Sommadossi, XJ Zhou |
Antimicrobial agents and chemotherapy | 1998 |
Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-( R )-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults
SG Deeks, P Barditch-Crovo, PS Lietman, F Hwang, KC Cundy, JF Rooney, NS Hellmann, S Safrin, JO Kahn |
Antimicrobial agents and chemotherapy | 1998 |
Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection.
Peter K, Gambertoglio JG |
Pharmaceutical Research | 1998 |
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively
AB Wout, LJ Ran, MD de Jong, M Bakker, R Leeuwen, DW Notermans, AE Loeliger, F Wolf, SA Danner, P Reiss, CA Boucher, JM Lange, H Schuitemaker |
Journal of Clinical Investigation | 1997 |
In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine
M Tanaka, RV Srinivas, T Ueno, MF Kavlick, FK Hui, A Fridland, JS Driscoll, H Mitsuya |
Antimicrobial agents and chemotherapy | 1997 |
Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides
P Clayette, N Dereuddre-Bosquet, M Martin, P Fretier, D Dormont |
Antimicrobial agents and chemotherapy | 1997 |
Increased activation of the combination of 3'-azido-3'-deoxythymidine and 2'-deoxy-3'-thiacytidine in the presence of hydroxyurea
S Palmer, S Cox |
Antimicrobial agents and chemotherapy | 1997 |
Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease
P Brouwers, M Hendricks, JA Lietzau, JM Pluda, H Mitsuya, S Broder, R Yarchoan |
AIDS | 1997 |
Lamivudine (3TC) phosphorylation and drug interactions in vitro
S Kewn, GJ Veal, PG Hoggard, MG Barry, DJ Back |
Biochemical Pharmacology | 1997 |
2′-Fluoro-2′,3′-Dideoxyarabinosyladenine (F-ddA): Activity against Drug-Resistant Human Immunodeficiency Virus Strains and Clades A-E
JS Driscoll, DL Mayers, JP Bader, OS Weislow, DG Johns, RW Buckheit |
Antiviral Chemistry & Chemotherapy | 1997 |
Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
Adkins JC, Peters DH, Faulds D |
Drugs | 1997 |
Inhibition of Murine AIDS by Combination of AZT and Dideoxycytidine 5'-Triphosphate
A Fraternale, A Casabianca, L Rossi, L Chiarantini, G Brandi, G Aluigi, GF Schiavano, M Magnani |
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology | 1996 |
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds
L Rabin, M Hincenbergs, MB Moreno, S Warren, V Linquist, R Datema, B Charpiot, J Seifert, H Kaneshima, JM McCune |
Antimicrobial agents and chemotherapy | 1996 |
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
EJ Arts, MA Wainberg |
Antimicrobial agents and chemotherapy | 1996 |
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases
JM Cherrington, MD Fuller, AS Mulato, SJ Allen, SC Kunder, MA Ussery, Z Lesnikowski, RF Schinazi, JP Sommadossi, MS Chen |
Antimicrobial agents and chemotherapy | 1996 |
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)
A Fol, KM Sogocio, B Anderson, M Kavlick, MW Saville, MA Wainberg, Z Gu, JM Cherrington, H Mitsuya, R Yarchoan |
Antiviral Research | 1996 |
Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro
K Ijichi, M Fujiwara, K Mori, M Morozumi, H Machida, S Shigeta, K Konno, T Yokota, M Baba |
Antiviral Research | 1996 |
Determination of HIV-1 susceptibility to reverse transcriptase (RT) inhibitors by a quantitative cell-free RT assay
R Greene |
Clinical and Diagnostic Virology | 1996 |
A Randomized Trial (ISS 901) of Switching to Didanosine Versus Continued Zidovudine after the Diagnosis of AIDS
S Vella, M Floridia, LG Dally, C Tomino, V Fragola, LE Weimer, F Milazzo, F Mazzotta, M Moroni, G Pastore, G Scalise, A Sinicco, L Ortona, BD Rienzo, F Dianzani |
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology | 1996 |
Les anti-rétroviraux
J Durant, P Dellamonica |
Médecine et Maladies Infectieuses | 1996 |
Anti-human immunodeficiency virus type 1 activities of dideoxynucleoside phosphotriester derivatives in primary monocytes/macrophages
C Thumann-Schweitzer, G Gosselin, C Périgaud, S Benzaria, JL Girardet, I Lefebvre, JL Imbach, A Kirn, AM Aubertin |
Research in Virology | 1996 |
Drug Evaluation: Anti-infectives: Saquinavir: A review of its development, pharmacological properties and clinical use
G Moyle |
Expert Opinion on Investigational Drugs | 1996 |
Intracellular Metabolism of 3′-Azido-3′-Deoxythymidine in the Presence of Ganciclovir or Foscarnet
S Palmer, H Rasmussen, J Harmenberg, S Cox |
Antiviral Chemistry & Chemotherapy | 1996 |
Drug Resistance
WN Hait |
1996 | |
Antiviral Chemotherapy 4
J Mills, PA Volberding, L Corey |
1996 | |
Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA
EJ Arts, JP Marois, Z Gu, SF Grice, MA Wainberg |
Journal of virology | 1996 |
Current knowledge and future prospects for the use of HIV protease inhibitors.
Moyle G, Gazzard B |
Drugs | 1996 |
HIV-1 chemotherapy and drug resistance
R Daquila |
Clinical and Diagnostic Virology | 1995 |
Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells
T Shirasaka, S Chokekijchai, A Yamada, G Gosselin, JL Imbach, H Mitsuya |
Antimicrobial agents and chemotherapy | 1995 |
Sanctuary growth of human immunodeficiency virus in the presence of 3'-azido-3'-deoxythymidine
DJ Medina, PP Tung, MB Lerner-Tung, CJ Nelson, JW Mellors, RK Strair |
Journal of virology | 1995 |
Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus
WY Gao, DG Johns, S Chokekuchai, H Mitsuya |
Proceedings of the National Academy of Sciences | 1995 |
Drug interactions with zidovudine phosphorylation in vitro
PG Hoggard, GJ Veal, MJ Wild, MG Barry, DJ Back |
Antimicrobial agents and chemotherapy | 1995 |
Minireview: nucleotide prodrugs
RJ Jones, N Bischofberger |
Antiviral Research | 1995 |
Aromatic amino acid phosphoramidate di- and triesters of 3′-azido-3′-deoxythymidine (AZT) are non-toxic inhibitors of HIV-1 replication
CR Wagner, EJ McIntee, RF Schinazi, TW Abraham |
Bioorganic & Medicinal Chemistry Letters | 1995 |
Development of a Human Thymic Organ Culture Model for the Study of HIV Pathogenesis
ML Bonyhadi, L Su, J Auten, JO McCUNE, H Kaneshima |
AIDS Research and Human Retroviruses | 1995 |
In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI
S Chokekijchai, T Shirasaka, JN Weinstein, H Mitsuya |
Antiviral Research | 1995 |
Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter
JJ Eron, SL Benoit, J Jemsek, RD MacArthur, J Santana, JB Quinn, DR Kuritzkes, MA Fallon, M Rubin |
New England Journal of Medicine | 1995 |
Metabolism of zidovudine
GJ Veal, DJ Back |
General Pharmacology: The Vascular System | 1995 |
Zalcitabine (ddC) Phosphorylation and Drug Interactions
GJ Veal, MG Barry, DJ Back |
Antiviral Chemistry & Chemotherapy | 1995 |
Host Cell Dependence of Human Immunodeficiency Virus Type-1 Drug Resistance Profiles and Tissue Culture Selection Patterns
H Salomon, Z Gu, Q Gao, K Nagai, J Hiscott, MA Wainberg |
Antiviral Chemistry & Chemotherapy | 1995 |
T-lymphocytes from AIDS Patients Are Unable to Synthesize Ribonucleotides de Novo in Response to Mitogenic Stimulation
M Bofill, LD Fairbanks, K Ruckemann, M Lipman, HA Simmonds |
The Journal of biological chemistry | 1995 |
Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection:
BN Stretcher |
Clinical Pharmacokinetics | 1995 |
Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group
DL Mayers, AJ Japour, JM Arduino, SM Hammer, R Reichman, KF Wagner, R Chung, J Lane, CS Crumpacker, GX McLeod |
Antimicrobial agents and chemotherapy | 1994 |
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro
T Mazzulli, S Rusconi, DP Merrill, RT D'Aquila, M Moonis, TC Chou, MS Hirsch |
Antimicrobial agents and chemotherapy | 1994 |
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes
SD Malley, JM Grange, F Hamedi-Sangsari, JR Vila |
Proceedings of the National Academy of Sciences | 1994 |
Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells
GJ Veal, MJ Wild, MG Barry, DJ Back |
British Journal of Clinical Pharmacology | 1994 |
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor
EV Connell, MC Hsu, DD Richman |
Antimicrobial agents and chemotherapy | 1994 |
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
DD Richman, D Havlir, J Corbeil, D Looney, C Ignacio, SA Spector, J Sullivan, S Cheeseman, K Barringer, D Pauletti |
Journal of virology | 1994 |
Comparison of the efficacy of AZT and PMEA treatment against acute SIVmne infection in macaques
CC Tsai, KE Follis, R Grant, A Sabo, R Nolte, C Bartz, N Bischofberger, R Benveniste |
Journal of Medical Primatology | 1994 |
Chemistry and Anti-HIV Activity of 2′-β-Fluoro-2′,3′-dideoxyguanosine
H Ford, JS Driscoll, M Siddiqui, JA Kelley, H Mitsuya, T Shirasaka, DG Johns, VE Marquez |
Nucleosides and Nucleotides | 1994 |
In vitro studies of the toxicity of nucleoside analogues used in the treatment of HIV infection
OP Flint |
Toxicology in Vitro | 1994 |
Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA BIS(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine
C Pericaud, AM Aubertin, S Benzaria, H Pelicano, JL Girardet, G Maury, G Gosselin, A Kirn, JL Imbach |
Biochemical Pharmacology | 1994 |
Enzymatic phosphorylation and pyrophosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2',3'-dideoxyinosine
JF Navé, A Eschbach, D Wolff-Kugel, S Halazy, J Balzarini |
Biochemical Pharmacology | 1994 |
Intracellular Metabolism of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine in Combination in the Absence and Presence of Ribavirin
S Palmer, S Cox |
Antiviral Chemistry & Chemotherapy | 1994 |
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2‘,3‘-dideoxynucleoside analogs in resting and activated human cells
WY Gao, R Agbaria, JS Driscoll, H Mitsuya |
The Journal of biological chemistry | 1994 |
Present Status and Future Prospects for HIV Therapies
MI Johnston, DF Hoth |
Science | 1993 |